Digest Network Come funziona
Network
/
Società
Mi
Non verificato

Minerva Neurosciences, Inc

Di cosa scriviamo

Annunci EconomiciFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

17 comunicati stampa

Guarda tutti i comunicati
01/06/2026
Medicina Salute Benessere
Annunci Economici
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
18/05/2026
Medicina Salute Benessere
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
05/05/2026
Medicina Salute Benessere
Management/Organizzazione Aziendale
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
02/04/2026
Medicina Salute Benessere
Minerva Announces Leadership Transition
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
31/03/2026
Medicina Salute Benessere
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
25/03/2026
Medicina Salute Benessere
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
12/03/2026
Medicina Salute Benessere
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
11/03/2026
Medicina Salute Benessere
Management/Organizzazione Aziendale
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
04/03/2026
Medicina Salute Benessere
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
26/01/2026
Medicina Salute Benessere
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0